Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+, Mozilla Firefox 20+, Internet Explorer 11, Opera 15–18, Apple Safari 7, SeaMonkey 2.15-2.23

Search
  1. OncologyPRO
  2. Meeting resources
  3. ESMO 2016

Efficacy and safety of nivolumab monotherapy in patients with metastatic urothelial cancer (mUC) who have received prior treatment: Results from the phase II CheckMate 275 study

Date

08 Oct 2016

Session

Genitourinary tumours, non-prostate

Presenters

Matthew Galsky

Citation

Annals of Oncology (2016) 27 (6): 1-36. 10.1093/annonc/mdw435

Authors

M.D. Galsky1, M. Retz2, A.O. Siefker-Radtke3, A. Baron4, A. Necchi5, J. Bedke6, E.R. Plimack7, D. Vaena8, M. Grimm9, S. Bracarda10, J. Arranz Arija11, S.K. Pal12, C. Ohyama13, A. Saci14, A. Lambert15, S. Krishnan15, A. Azrilevich14, P. Sharma16

Author affiliations

  • 1 Oncology, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, 10029 - New York/US
  • 2 Department Of Urology, Klinikum Rechts der Isar, München/DE
  • 3 Genitourinary Medical Oncolgoy, The M. D. Anderson Cancer Center, Houston/US
  • 4 Division Of Hematology And Oncology, California Pacific Medical Center, San Francisco/US
  • 5 Experimental Oncology And Molecular Medicine, Fondazione IRCCS Istituto Nazionale dei Tumori, 20133 - Milan/IT
  • 6 Dept Of Urology, Universitätsklinikum Tübingen, Tübingen/DE
  • 7 Department Of Hematology/oncology, Fox Chase Cancer Center, PA 19111-2497 - Philadelphia/US
  • 8 Division Of Hematology, Oncology, And Bmt, University of Iowa, Iowa City/US
  • 9 Department Of Urology, University Hospital of Jena, Jena/DE
  • 10 Department Of Oncology, Ospedale San Donato and U.O.C. of Medical Oncology, 52100 - Arezzo/IT
  • 11 Servicio De Oncologia Medica, Hospital General Universitario Gregorio Marañon, 28007 - Madrid/ES
  • 12 Medical Oncology And Experimental Therapuetics, City of Hope, 91010 - Duarte/US
  • 13 Department Of Urology, Hirosaki University, Hirosaki/JP
  • 14 Research And Development, Bristol-Myers Squibb, Princeton/US
  • 15 Biostatistics, Bristol-Myers Squibb, Princeton/US
  • 16 Department Of Genitourinary Medical Oncology, The University of Texas M.D. Anderson Cancer Center, Houston/US
More

Resources

Login to access the resources on OncologyPRO.

If you do not have an ESMO account, please create one for free.

Login

Abstract 3309

Background

Chemotherapy for platinum-resistant advanced mUC yields poor objective response rates (ORR) and overall survival (OS). Nivolumab (NIVO) recently showed promising efficacy and safety in the CheckMate 032 phase I/II study (NCT01928394) in this setting. The current larger study, CheckMate 275 (NCT02387996), investigated efficacy and safety of NIVO in patients (pts) with mUC or surgically unresectable locally advanced UC that progressed after platinum-based chemotherapy.

Methods

In this open-label, single-arm, phase II study, pts received NIVO 3 mg/kg IV every 2 weeks until progression or unacceptable toxicity. The primary endpoint was ORR confirmed by blinded independent review committee (RECIST 1.1). Outcomes were evaluated in all treated pts and by tumor programmed death-1 ligand 1 (PD-L1) expression (≥1% and ≥5%; Dako PD-L1 PharmDx). Biomarkers were analyzed for association between response, UC subtype (by The Cancer Genome Atlas), and immune gene signature expression.

Results

At 7 mo of median follow-up, 24.4% of pts remain on therapy. Confirmed ORR was 19.6% (95% CI 15.0–24.9), and 16.1% (95% CI 10.5–23.1) in pts with low to no PD-L1 expression (Table). Median duration of response was not reached, with responses ongoing in 76.9% of responders. Median progression-free survival was 2.00 mo (95% CI 1.87–2.63); median OS was 8.74 mo (95% CI 6.05–not estimable). Grade 3–4 treatment-related adverse events occurred in 18% of pts (grade 5, 1%), mainly fatigue and diarrhea (2% each). Basal 1 UC subtype had the highest proportion of responders and strongest interferon gamma (IFNγ) gene signature expression. Quality of life was stable over time.

Conclusions

In this large study in advanced/unresectable UC, NIVO had clinically meaningful efficacy and a manageable safety profile. Efficacy benefit of NIVO was seen across all PD-L1 subgroups.

Total PD-L1

Clinical trial identification

NCT02387996

Legal entity responsible for the study

Matthew D. Galsky

Funding

Funding for this study was provided by Bristol-Myers Squibb

Disclosure

M.D. Galsky: Stock ownership with Dual Therapeutics. Consulted with Genentech, Merck, Novartis, Astellas. Received research funding from BMS, Dendreon, Janssen, Novartis, and Merck. Intellectual properties with Mount Sinai school of Medicine. M. Retz: Received consulting and advising from BMS and Roche. A.O. Siefker-Radtke: Advisory board member of Janssen, Eisai, ad Genentech. Corporate sponsored research with Janssen, Millennium, Genentech, and AstraZeneca. A. Baron: Speakers bureau with Eli Lilly, Genetech, Merck, and BMS. Received research funding from BMS, Merck, and Genetech. A. Necchi: Consultant/advisor with Roche, MSD, Pierre Fabre, and Celgene. Research funding received from Millennium-Takeda, Amgen, and GSK. Travel and and expenses have been received from Roche, MSD, Pierre Fabre, Celgene, and Pfizer. J. Bedke: Consultant and advisor for Pfizer, Novartis, Bayer and Nektar. Research funding received from BMS, Novartis, Roche, and Immatics. Travel, accomodations, and expenses received from Bayer E.R. Plimack: Consultant/Advisor for Merck, Dendreon, Novartis, BMS, Pfizer, GSK, Acceleron Pharma, Genetech, Roche. Research fundin received from Merck, BMS, GSK, Accleron Pharma, Dendreon, Lilly, and AZ. Also have a US patent relating to health and research. D. Vaena: Site principal investigator at University of Iowa for industry trials: Bristol Myers Squibb, Argos Therapeutics, Glaxo Smith Kline, Bayer, Genentech Roche, Tekmira, Acerta, Tracon, M-O. Grimm: Honoraria received from Janssen Cilag, Sanofi, Astellas, Hexal, Bayer, Pfizer, Teva, Jenapharm, BMS, Pierre Fabre, and Novartis. Consulting role with GSK, Novartis, Pfizer, Bayer, BMS, and Sanofi. Research funding received from Novartis. S. Bracarda: Honoraria received from Pfizer, Novartis, Astellas, Bayer, and BMS. Advisory Board Member for Pfizer, Astellas, BMS, Novartis, Exelixis, and Roche. J. Arranz Arija: Consulthing or Advisory: Novartis, Jansen, Sanofi Travel, Accomodations, Expenses: Astellas S.K. Pal: Honoraria from Novartis, Medivation and Astellas Pharma, and receives consulting fees from Pfizer, Novartis, Aveo, Genentech, Exelixis, BMS, Astellas and GSK. A. Lambert: BMS employee and stock owner. S. Krishnan: Employment: Bristol-Myers Squibb Stock: Bristol-Myers Squibb A. Azrilevich: Employee and stockholder with BMS. Received travel and expenses from BMS. P. Sharma: compensation/leadership role and stock with Kite, Jounce, Evelo, and Neon. Consultant role with GSK. Amgen, BMS, and AZ. Own patient licensed to Jounce and patients licensed to BMS, Jounce Merck. Research as principal investigator for BMS, GSK, and AZ. All other authors have declared no conflicts of interest.

Resources from the same session

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings

  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and can only be disabled by changing your browser preferences.